Explore the Agenda
7:00 am Breakfast Briefing Hosted By Versiti
*Invitation only
8:00 am Chair’s Opening Remarks
Unlocking Precision Through Data at Scale with AI‑Driven Integration Across Omics, Imaging & Clinical Insight
8:10 am Accelerating Target Discovery & Precision Medicine Through AI-Enabled Integration of Human Genetics & Multimodal Data
- Building FAIR, AI-enabled disease data ecosystems to accelerate translational discovery and cross-domain decision making
- Combining human genetics, multimodal biology, and AI to identify and prioritize causal therapeutic targets
- Resolving disease endotypes through multimodal data integration to enable patient stratification and precision medicine
8:30 am Cancer Biology Through 5hmC Liquid Biopsy: From Early Detection to Drug Development
- 5hmC is an epigenetic mark enriched at active gene bodies, enhancers, and promoters transitioning to an active state. Analysis of 5hmC in cell-free DNA therefore provides a window into active disease biology directly from blood
- Genome-wide 5hmC profiling with ClearNote Health’s Virtuoso epigenomic platform enables cancer detection, subtype classification, treatment response prediction, and longitudinal disease monitoring with a single, liquid biopsy-based assay
- Clinical evidence across lung, prostate, colorectal, and pancreatic cancers supports applications spanning early detection and drug development, establishing 5hmC profiling by Virtuoso as a versatile epigenomic tool across the oncology pipeline
9:00 am Panel Discussion: Applying AI & Advanced Data Analytics to Transform Biomarker Discovery & Clinical Trial Strategy for Improved Precision Medicine Programs
Presentation Details to be Announced
9:30 am Session Reserved for Tempus
Presentation Details to be Announced
10:00 am The Multimodal Imperative: Scaling Precision with AI-Integrated Data
- What’s Possible: Uncovering the lost signals in today’s disjoined multimodal data landscape
- Key Consideration: Building an AI-ready data foundation for multimodal data, designed to address security, compliance, and scalability requirements, while enabling federated governance so data remains sovereign and cross-institutional insight remains possible
- The AI Layer: How a connected multimodal foundation improves the ability to answer complex cross-domain questions, democratizes access for all users, and shortens the path from molecular insight to clinical decision
10:20 am Morning Break & Refreshments
10:50 am One-to-One Meetings & Structured Networking
Biomarker Discovery & Translation
Clinical & CDx Development
Rx–Dx Commercialization & Adoption
Digital Pathology & Spatial Biomarkers
Multimodal & AI-Enabled Precision Medicine
Biomarker Discovery & Translation
Innovation in Liquid Biopsy to Improve Disease Monitoring & Response Prediction for Earlier, Informative Precision‑Therapy Decisions
11:20 am From Market Insight to Clinical Impact: Developing an Ultra-Sensitive ESR1 ddPCR
Vice President, Business Development, Biodesix
- Why ESR1 now: ESR1 has become a time-sensitive, longitudinal ctDNA biomarker, enabling earlier insight into endocrine resistance as ER-targeted therapies expand
- Monitoring needs different tools: Reliable resistance tracking requires ultrasensitive, reproducible detection at very low allele fractions, positioning ddPCR as a strong fit for longitudinal monitoring
- From insight to action: A real-world case study showing how market and clinical needs translate into a validated ESR1 ddPCR assay that supports meaningful R&D decisions
11:50 am Definition of the Best Practices in Clinical Utility of Liquid Biopsy: Clinical Guideline, Technologies, Cost-Effectiveness, Reimbursement, a Unidirectional or Multidirectional Path
Head, Clinical Genomics, Clinical Measurements Sciences, EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany
- Decipher the tumor shedding mechanism
- Precision medicine-driven cut-off strategy implmentation
- Tired fit-for-purpose liquid biopsy solutions combined with real-world genomic data mining
- 1ctDNA-guided treatment and consideration of cost-effectiveness thresholds
12:10 pm Accelerating Biomarker-Driven Therapy & Clinical-Trial Enrollment with Rapid Front-Line NGS
Associate Medical Director, Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Memorial Sloan Kettering Cancer Center
- Learn how rapid front-line targeted NGS enables earlier detection of actionable biomarkers, supporting timely precision oncology treatment decisions and companion diagnostic strategies
- Discover best practices for developing, validating, and implementing a rapid targeted NGS assay that complements comprehensive genomic profiling while accelerating biomarker identification
- Explore how rapid genomic insights can expedite biomarker-driven clinical trial enrollment, improve access to targeted therapies, and support pharmaceutical and diagnostic partners developing companion diagnostics
- See how optimized workflows using the Illumina MiSeq™ i100 Series and Hamilton STARlet can reduce NGS turnaround times, helping bring biomarker-guided therapies and CDx solutions to patients faster
12:40 pm Session Reserved for Predicine
Presentation Details to be Announced
12:50 pm Panel Discussion: Transforming Patient Monitoring Through Innovation in Liquid Biopsy Analytes, Detection Sensitivity & Data Interpretation
Associate VP, Companion Diagnostic Development (Cdx), Merck
Head, Clinical Genomics, Clinical Measurements Sciences, EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany
Senior Director, Clinical Biomarkers, Clinical Development, Eikon Therapeutics
Vice President, Translational Sciences, Compass Therapeutics
- What are the most impactful recent innovations in liquid biopsy biomarkers, and how can these be robustly validated and effectively integrated into clinical trial designs?
- How can drug-diagnostic stakeholders build high-value, collaborative frameworks to advance liquid biopsy technologies, particularly in improving detection sensitivity, standardization, and data interpretation?
Clinical & CDx Development
Rx–Dx Commercialization & Adoption
Digital Pathology & Spatial Biomarkers
Multimodal & AI-Enabled Precision Medicine
1:10 pm Lunch Break & Networking
1:10 pm Lunch & Learn Hosted By Natera
*Invitation only
1:40 pm One-to-One Meetings & Structured Networking
Biomarker Discovery & Translation
Clinical & CDx Development
Rx–Dx Commercialization & Adoption
Digital Pathology & Spatial Biomarkers
Multimodal & AI-Enabled Precision Medicine
Biomarker Discovery & Translation
From Biomarker Discovery to Early Clinical Translation Advancing Precision Oncology Through Next-Generation Panels
2:10 pm Session Reserved for Sentry Dx
Presentation Details to be Announced
2:40 pm Advancing Precision Oncology: Developing Translational Biomarkers for a Novel Mitochondrial-Targeted Therapy
President & Chief Executive Officer, Bantam Pharmaceutical LLC
- Therapeutic programs with novel targets and mechanisms of action present significant challenges when developing translational biomarkers to select patients and characterize treatment responses
- BTM-3566 modulates mitochondrial dynamics as a unique therapeutic strategy for treating tumors resistant to standard of care and those tumors with aggressive genomic profiles
- A summary of the scientific progression of this drug and the considerations for various biomarker strategies explored will be presented as well as current clinical study plans to develop a precision medicine product
3:00 pm Session to be Confirmed
Inquire about remaining partnership opportunities at sponsor@hansonwade.com
3:10 pm Panel Discussion: Navigating Biomarker Complexity as a Biotech to Build Smarter Precision Oncology Strategies that Maximize Clinical & Commercial Impact
Executive Director, Translational Biomarkers & Diagnostics, Immunome
Acting Chief Development Officer, Incendia Therapeutics
Director, Clinical Biomarkers, Agenus
Vice President, Translational Medicine & Research, Pyxis Oncology
- How to determine when a biomarker‑enabled strategy truly advances the program, balancing scientific risk, portfolio focus, and capital efficiency?
- What can biotech do to evaluate partnership models that foster innovation while ensuring operational feasibility, sustainable costs, and long-term scalability of CDx?
- When to integrate biomarker considerations into early clinical development without overburdening trial design, patient recruitment, or organizational capacity?
Clinical & CDx Development
Rx–Dx Commercialization & Adoption
Digital Pathology & Spatial Biomarkers
Multimodal & AI-Enabled Precision Medicine
3:40 pm Afternoon Break & Dedicated One-to-One Meetings
Driving Precision Medicine in Unmet Patient Populations with Biomarker Designs for Novel Assays & Small Cohort Studies
4:05 pm Chairs Opening Afternoon Remarks
4:10 pm Session Reserved for Personalis
Presentation Details to be Announced
4:40 pm Neurofilament: The Journey of a General Marker of Axonal Damage to a Biomarker with Clinical Utility in Multiple Sclerosis & Future Utility in Multiple Indications
- Overview of evidence generation for neurofilament light chain over the last 10 years
- Importance of robust diagnostic testing systems with established performance characteristics for neurofilament testing in clinical trials
- Drug-diagnostic co-development in MS and neurodegenerative disorders
5:00 pm Session Reserved for Thermo Fisher Scientific
Presentation Details to be Announced
5:30 pm Translational Pharmacology & Biomarker Strategy in Drug Discovery & Development
- Approval of a drug requires a statistically significant improvement in an outcome measure. Outcome measures, reflecting how patients feels or function, can require many patients and long studies to reach statistical significance
- Biomarkers, object measures of biological changes, can be used to select the dose and to provide evidence of disease modulation with fewer patients and in less time
- Preclinical studies can be utilized to link a biomarker to subsequent outcome measures